Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.

Oxurion NV

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Aldeyra Therapeutics, Inc.

Imcyse is a clinical-stage biopharmaceutical company focused on advancing the development of specific immunotherapies for severe autoimmune diseases. The company's unique ImotopeTM platform aims to address a wide range of immunologic diseases.

Imcyse

SIEHT is a healthcare provider specializing in eye care services, including cataract surgery, LASIK vision correction, glaucoma treatment, and general eye exams.

SIEHT

Oxurion is a biotech research company specializing in developing treatments for retinal diseases, specifically Geographic Atrophy and Age-related Macular Degeneration. The company focuses on innovative approaches to eye care.

Metric
Company Name	Oxurion NV	Aldeyra Therapeutics, Inc.	Imcyse	SIEHT
Symbol	OXUR	ALDX
MSH ID	COM:OXURION	COM:ALDEYRA	COM:IMCYSE	COM:SIEHT
Market	STOCKS	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Biopharmaceuticals	Optometry
Country	BE	US	BE	US
Stage
Employee Count	20	10
Website	oxurion.com	aldeyra.com	imcyse.com	sieht.com
LinkedIn
Founders

Metric
Market Cap	2.59M	202.01M
Enterprise Value
Monthly Web Traffic			419
Web Traffic Growth			-0.85
Valuation
Raised Capital

Metric
Revenue	277.79K
Revenue (LTM)
Revenue (NTM)
Gross Profit	109.85K
EBITDA	-14.24M
Operating Income	-12.79M
Net Income	-20.04M
EPS	-0.01
Diluted EPS	-0.01
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	-0.16
Operating Profit Margin	-32.84
EBITDA Margin	-51.27
Net Profit Margin	-54.03
Return on Equity	4.21
Return on Assets	-2.35
Return on Capital Employed	2.47

COM:OXURION

Oxurion

Last Close

0.32

25/11 09:23

Market Cap

2.46M

Beta: -

Volume Today

39.22K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.00
P/B Ratio	-0.01
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	15.36
EV Multiple	1.55

Metric
Days Sales Outstanding
Days Payables Outstanding	3.59K
Days Inventory Outstanding	0.45
Operating Cycle	3.72K
Cash Conversion Cycle	479.87
Asset Turnover	0.08

Metric
Operating Cash Flow	-10.31M
Free Cash Flow	-10.32M
Cash Flow to Debt	-0.39
Operating Cash Flow/Sales	-17.83
Free Cash Flow Yield	-11.06

Metric
Cash & Equivalents	1.72M
Accounts Receivable	2.83M
Inventory	135.20K
Goodwill
Debt to Capitalization	6.89
Debt to Assets	0.67
Current Ratio	0.58
Quick Ratio	0.40

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	1.57
R&D to Revenue	26.87
SG&A to Revenue	7.45